Day One Biopharmaceuticals saw its shares surge 26.7% during the most recent trading session on volume of 5.2 million shares, more than double its 30-day average of 2.1 million. The move came after research firm Orion Analytics highlighted an uptick in institutional interest, citing five new 13F filings from hedge funds over the past two weeks. Despite the strong session, consensus earnings‐per‐share estimates for fiscal 2026 have been revised downward by an average of 4% over the last month, suggesting analysts remain cautious about near-term profitability drivers.

At the 44th Annual J.P. Morgan Healthcare Conference, CEO Jeremy Bender reported that OJEMDA has treated over 1,000 pediatric patients since approval, driving $95 million in revenue during the first nine months of 2025. Management reiterated guidance for full-year R&D expenses of $180 million and G&A costs of $60 million, projecting a cash runway into late 2027 based on the current $450 million balance. The company also provided an update on its Phase II trial of D1B-102 for rare lymphatic disorders, with top‐line data expected in Q3 2026 and enrollment already at 70% of the 60-patient target.